CN112841472A - 一种木姜叶柯饮料及其制备方法 - Google Patents
一种木姜叶柯饮料及其制备方法 Download PDFInfo
- Publication number
- CN112841472A CN112841472A CN202110015884.8A CN202110015884A CN112841472A CN 112841472 A CN112841472 A CN 112841472A CN 202110015884 A CN202110015884 A CN 202110015884A CN 112841472 A CN112841472 A CN 112841472A
- Authority
- CN
- China
- Prior art keywords
- lemon
- lithocarpus litseifolius
- extract
- raw materials
- beverage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001365741 Lithocarpus litseifolius Species 0.000 title claims abstract description 61
- 235000013361 beverage Nutrition 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 235000005979 Citrus limon Nutrition 0.000 claims abstract description 53
- 239000002994 raw material Substances 0.000 claims abstract description 20
- 229930189775 mogroside Natural products 0.000 claims abstract description 17
- 239000000463 material Substances 0.000 claims abstract description 14
- 235000013399 edible fruits Nutrition 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000001116 FEMA 4028 Substances 0.000 claims description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 6
- 229960004853 betadex Drugs 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 244000248349 Citrus limon Species 0.000 claims 16
- 238000000034 method Methods 0.000 claims 3
- 244000131522 Citrus pyriformis Species 0.000 abstract description 37
- 230000000694 effects Effects 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000008280 blood Substances 0.000 abstract description 16
- 235000013305 food Nutrition 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000002924 anti-infective effect Effects 0.000 abstract description 2
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 241000587213 Litsea coreana Species 0.000 abstract 1
- 241000633855 Litsea pungens Species 0.000 abstract 1
- 241001122767 Theaceae Species 0.000 description 14
- 235000009508 confectionery Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 229940126902 Phlorizin Drugs 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- IOUVKUPGCMBWBT-UHFFFAOYSA-N phloridzosid Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-UHFFFAOYSA-N 0.000 description 6
- 235000019139 phlorizin Nutrition 0.000 description 6
- 239000001689 FEMA 4674 Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229930182647 Trilobatin Natural products 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 235000011837 pasties Nutrition 0.000 description 4
- IOUVKUPGCMBWBT-GHRYLNIYSA-N phlorizin Chemical compound O[C@@H]1[C@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 IOUVKUPGCMBWBT-GHRYLNIYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- GSTCPEBQYSOEHV-QNDFHXLGSA-N trilobatin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C=C1O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 GSTCPEBQYSOEHV-QNDFHXLGSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 244000185386 Thladiantha grosvenorii Species 0.000 description 3
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 2
- 108091052347 Glucose transporter family Proteins 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000219428 Fagaceae Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 235000009815 Momordica Nutrition 0.000 description 1
- 241000218984 Momordica Species 0.000 description 1
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- LUJAXSNNYBCFEE-UHFFFAOYSA-N Quercetin 3,7-dimethyl ether Natural products C=1C(OC)=CC(O)=C(C(C=2OC)=O)C=1OC=2C1=CC=C(O)C(O)=C1 LUJAXSNNYBCFEE-UHFFFAOYSA-N 0.000 description 1
- PUTDIROJWHRSJW-UHFFFAOYSA-N Quercitrin Natural products CC1OC(Oc2cc(cc(O)c2O)C3=CC(=O)c4c(O)cc(O)cc4O3)C(O)C(O)C1O PUTDIROJWHRSJW-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OXGUCUVFOIWWQJ-XIMSSLRFSA-N acanthophorin B Natural products O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-XIMSSLRFSA-N 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- ZHKVKULEJZXSLW-KZZGZOJNSA-N beta-daucosterol Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(O)[C@H]3CC[C@]12C)O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C ZHKVKULEJZXSLW-KZZGZOJNSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- PJWPOUFMMWFJOL-UHFFFAOYSA-N beta-sitosterol-beta-D-glucoside Natural products CCC(CCC(C)C1CCC2C3C=CC4CC(CCC4(C)C3CCC12C)OC5OC(CO)C(O)C(O)C5O)C(C)C PJWPOUFMMWFJOL-UHFFFAOYSA-N 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- OEKUVLQNKPXSOY-UHFFFAOYSA-N quercetin 3-O-beta-D-glucopyranosyl(1->3)-alpha-L-rhamnopyranosyl(1->6)-beta-d-galactopyranoside Natural products OC1C(O)C(C(O)C)OC1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OEKUVLQNKPXSOY-UHFFFAOYSA-N 0.000 description 1
- QPHXPNUXTNHJOF-UHFFFAOYSA-N quercetin-7-O-beta-L-rhamnopyranoside Natural products OC1C(O)C(O)C(C)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 QPHXPNUXTNHJOF-UHFFFAOYSA-N 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Non-Alcoholic Beverages (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及保健饮品技术领域,具体为一种木姜叶柯饮料及其制备方法;以木姜叶柯提取物、罗汉果苷及柠檬提取物为主要原料,各原料按重量百分比的含量为:木姜叶柯提取物5%~60%、罗汉果苷1%~20%、柠檬提取物5%~40%,余量为辅料,所述各原料重量百分比的总和不超过100%;本发明制成的木姜叶柯饮料,不仅能保持原有风味和对人体有益的成分,还具有中草药功效,绿色健康,口感效果好,具有一定的保健功效;作为普通保健产品,可以改善记忆,维持血糖正常水平,并且还有抗感染的功效,同时由于无糖,不会增加体重,对减肥人士友好。本发明生产工艺简单,易实现,生产成本低,具有较大推广应用价值。
Description
技术领域
本发明涉及保健饮品技术领域,具体为一种木姜叶柯饮料及其制备方法。
背景技术
随着社会的发展与科技的进步,人们生活水平不断提高,人们的饮食结构也随之发生改变,糖类、蛋白质和脂肪的摄入量不断增加,而运动量却相对减少,高血糖、高血脂等代谢性问题呈现不断上升的趋势,这也加剧了糖尿病、动脉粥样硬化、冠心病、脂肪肝等疾病发病率的升高。对于血糖、血脂,如何控制二者在正常水平,是防止代谢类疾病进一步发展与恶化的关键。因此,有效控制血糖和血脂水平,成为人们在日常生活中需要注意的问题。
目前,对于高血糖、高血脂的治疗,主要是服用降糖药及降血脂药物,如:二甲双胍、格列齐特、阿卡波糖等降糖药以及辛伐他汀、吉非贝齐等降血脂药。这些药物虽然能在较短时间内改善高血糖及高血脂,但存在病人顺应性差、疗效低、不良反应较多等问题,病人难以长期服用。因此,能否在传统中医药理论指导下,借助现代科技手段,采用日常食物特别是“药食同源”原料的配伍,找到合适的功能性配方食品,通过病人较长时间食用,改善其血糖和血脂水平,成为调节血糖、血脂产品的研发热点。
木姜叶柯为壳斗科植物木姜叶柯Lithocarpus litseifolius(Hance)Chun.的干燥嫩叶,为药食同源原料,2017年作为新食品原料使用,具有茶、糖、药三种特性,制茶后,冲泡有甜味,长江以南多数山区居民用其代茶饮,通称甜茶。木姜叶柯性寒味甘、苦,具有清热解毒、化痰、祛风、降压的作用,主治湿热泻痢、肺热咳嗽、痈疽疮疡、皮肤瘙痒、高血压。现代研究表明,木姜叶柯中的黄酮类成分具有降血糖、降血压、降脂及抗过敏、抗炎等作用,尤其根皮苷在糖尿病及其并发症的防治中具有独特的效果。
木姜叶柯中含水量约30%,含有大量从体必需的氨基酸如谷氨酸、赖氨酸等,亦含许多微量元素如钾、钠、镁等以及维生素如VC、VE等。也含有普通茶叶都有的萜类、咖啡碱类、茶多酚类,更含有大量的黄酮类物质。其中,咖啡碱含量比普通茶叶低,经常饮用木姜叶柯不会导致精神亢奋、失眠等副作用。此外,木姜叶柯中萜类和黄酮类物质含量较高,根皮苷(0.41~20.45%)、三叶苷(0.2~25.53%)、6”-0-乙酰基三叶苷、3”-0-乙酰基根皮苷,2”-0-乙酰基根皮苷以及根皮素是甜茶中主要的黄酮类物质。还有学者从甜茶中分离出了二氢查耳酮吡喃葡糖苷、β-胡萝卜苷、β-谷甾醇、槲皮素、木犀草素、槲皮苷、齐墩果酸等化合物。根皮苷具有比葡萄糖更高的亲和力,可以与肾脏葡萄转运蛋白(GLUT)结合,从而抑制肾脏中的葡萄糖吸收和肠道吸收来使血糖正常化并整体降低血糖。三叶苷对α-葡萄糖苷酶的强抑制活性和对α-淀粉酶的中等抑制活性使其成为治疗Ⅱ型糖尿病的潜在抗糖尿病化合物,副作用少。在体外甜茶水提取物对人体乳腺癌细胞有细胞毒性和细胞凋亡的作用,也可以抑制体内肿瘤的生长,其机制可能诱导或抑制相应基因的表达有关。此外,从甜茶叶中分离出的羽扇类三萜类化合物,显示出强的抗HIV和抗氧化活性。
木姜叶柯中,嫩叶含有大量三叶苷,而老叶中含有大量的根皮苷。人们多利用木姜叶柯嫩叶作为茶产品,老叶作为茶产品口感不佳,因此大多被废弃。现有的木姜叶柯饮料口感涩、有效成分含量低。
发明内容
本发明的目的在于提供一种木姜叶柯饮料及其制备方法,以解决上述背景技术中所提出的问题。
为实现上述目的,本发明提供如下技术方案:
一种木姜叶柯饮料,以木姜叶柯提取物、罗汉果苷及柠檬提取物为主要原料,各原料按重量百分比的含量为:木姜叶柯提取物5%~60%、罗汉果苷1%~20%、柠檬提取物5%~40%,余量为辅料,所述各原料重量百分比的总和不超过100%。
进一步的,各原料按质量百分比的含量为:木姜叶柯提取物40%~60%、罗汉果苷5%~15%、柠檬提取物10%~30%,余量为辅料,所述各原料重量百分比的总和不超过100%。
优选的,各原料按质量百分比的含量为:木姜叶柯提取物40%、罗汉果苷15%、柠檬提取物18%,余量为辅料,所述各原料重量百分比的总和不超过100%。
进一步的,所述辅料为β-环糊精和碳酸氢纳。
本发明提供一种木姜叶柯饮料制备方法,包括以下步骤:
S1:将木姜叶柯老叶和嫩叶以及枝条冷冻干燥后粉碎,得到木姜叶柯粉末;
S2:将步骤S1得到的木姜叶柯粉末和70%的乙醇溶液加入压力容器罐,加入符合卫生标准的清水,将压力容器罐压力控制在10~20MPa,加入热水温度在80~100℃保持10min~50min,停止加热水,待压力容器罐内压力恢复到常压时,采用目数为2~8的金属过滤网过滤,收到滤液;
S3:当上清液流出完后再重复步骤S2对滤渣进一步压榨,继续收集滤液;
S4:将步骤S2和步骤S3中获得的滤液进行合并,再对合并后的滤液在浓缩仓进行减压浓缩,减压浓缩时浓缩仓内压强为80~90KPa,温度控制在60~80℃,减压浓缩时间为20min~25min,滤液浓缩成膏状;
S5:将浓缩膏喷雾干燥,粉碎过筛,备用;
S6:对柠檬原果进行清洗处理后除去外果皮,获得去外果皮柠檬果,将柠檬果切片机上切片3~4毫米,重量考虑一片9~12克,然后将柠檬片上的柠檬核去掉获得柠檬果片,将去除好的柠檬片放入微波灭菌机中灭菌,将柠檬果片先在-30℃冷冻4小时,然后在60℃真空干燥25小时,获得干柠檬果片,将柠檬果片进行粉碎获得柠檬果粉;
S7:在木姜叶柯浓缩膏粉中加入罗汉果苷、柠檬果粉和辅料,混合均匀,放入灭菌室进行115~125℃高温灭菌,冷却至94~96℃后取出,继续冷却至80~85℃后灌装,得到木姜叶柯饮料。
与现有技术相比,本发明的有益效果是:
本发明制成的木姜叶柯饮料,不仅能保持原有风味和对人体有益的成分,还具有中草药功效,绿色健康,口感效果好,具有一定的保健功效;作为普通保健产品,可以改善记忆,维持血糖正常水平,并且还有抗感染的功效,同时由于无糖,不会增加体重,对减肥人士友好。本发明生产工艺简单,易实现,生产成本低,具有较大推广应用价值。
具体实施方式
下面将结合本发明以下实施例,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1
1、提取物的制备:
S1:将木姜叶柯老叶和嫩叶以及枝条冷冻干燥后粉碎,得到木姜叶柯粉末;
S2:将步骤S1得到的木姜叶柯粉末和70%的乙醇溶液加入压力容器罐,加入符合卫生标准的清水,将压力容器罐压力控制在10~20MPa,加入热水温度在80~100℃保持10min~50min,停止加热水,待压力容器罐内压力恢复到常压时,采用目数为2~8的金属过滤网过滤,收到滤液;
S3:当上清液流出完后再重复步骤S2对滤渣进一步压榨,继续收集滤液;
S4:将步骤S2和步骤S3中获得的滤液进行合并,再对合并后的滤液在浓缩仓进行减压浓缩,减压浓缩时浓缩仓内压强为80~90KPa,温度控制在60~80℃,减压浓缩时间为20min~25min,滤液浓缩成膏状;
S5:将浓缩膏喷雾干燥,粉碎过筛,备用;
S6:对柠檬原果进行清洗处理后除去外果皮,获得去外果皮柠檬果,将柠檬果切片机上切片3~4毫米,重量考虑一片9~12克,然后将柠檬片上的柠檬核去掉获得柠檬果片,将去除好的柠檬片放入微波灭菌机中灭菌,将柠檬果片先在-30℃冷冻4小时,然后在60℃真空干燥25小时,获得干柠檬果片,将柠檬果片进行粉碎获得柠檬果粉;
S7:在木姜叶柯浓缩膏粉中加入罗汉果苷、柠檬果粉和辅料,混合均匀,放入灭菌室进行115~125℃高温灭菌,冷却至94~96℃后取出,继续冷却至80~85℃后灌装,得到木姜叶柯饮料。
2、成品的制备
(1)饮料剂型的选择
本发明的木姜叶柯饮料可以制成固定饮料(如膏剂)和瓶装液体饮料
(2)辅料的选择
在制备成品时可选择性的加入适合保健食品可接受的辅料。
本领域技术人员可以根据公知常识,根据最终产品的剂型选择相应的辅料。所述的剂型、辅料的选择不影响本发明的口感和保健效果。
实施例2
按重量百分比比例称取木姜叶柯提取物40%、罗汉果苷15%、柠檬提取物18%,加入β-环糊精和碳酸氢纳,混合均匀,制成膏状固体饮料。
实施例3
按重量百分比比例称取木姜叶柯提取物30%、罗汉果苷10%、柠檬提取物35%,加入β-环糊精和碳酸氢纳,混合均匀,制成膏状固体饮料。
实施例4
按重量百分比比例称取木姜叶柯提取物35%、罗汉果苷20%、柠檬提取物15%,加入β-环糊精和碳酸氢纳,混合均匀,制成膏状固体饮料。
实施例5
按重量百分比比例称取木姜叶柯提取物28%、罗汉果苷30%、柠檬提取物20%,加入β-环糊精和碳酸氢纳,混合均匀,制成膏状固体饮料。
一、本发明制成的木姜叶柯饮料经广西壮族自治区轻工产品质量检验站检验结果如下表1(编号:S2020-0848)和表2(编号:S2020-0849)
表1:
表2:
检测结果表明,本发明木姜叶柯饮料不含有重金属铅、有害菌,是一种低能量饮料。
二、采用本发明在高血糖高血脂模型大鼠上做实验结果表明:本发明所制备的木姜叶柯饮料对于高糖高脂模型大鼠,具有良好的治疗作用。可降低模型大鼠的血糖水平,恢复体重的增长,改善模型大鼠的糖耐量水平。对于模型大鼠的抗氧化指标,本发明产品可提高血清SOD、CAT水平,降低MDA水平,增强内源抗氧化系统活性,减轻氧化应激反应,缓解高血糖高血脂的发展。本发明还可降低模型大鼠的血脂水平,降低血清TC、TG、LDL-C含量,提高HDL-C含量,对高血糖高血脂模型具有良好的降血脂作用。本发明通过实验表明,将木姜叶柯与罗汉果及柠檬配合使用,其降血糖、降血脂作用均显著优于单独使用木姜叶柯、罗汉果、柠檬,三者有明显的协同增强作用。
尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (5)
1.一种木姜叶柯饮料,其特征在于:以木姜叶柯提取物、罗汉果苷及柠檬提取物为主要原料,各原料按重量百分比的含量为:木姜叶柯提取物5%~60%、罗汉果苷1%~20%、柠檬提取物5%~40%,余量为辅料,所述各原料重量百分比的总和不超过100%。
2.根据权利要求1所述的一种木姜叶柯饮料,其特征在于:各原料按质量百分比的含量为:木姜叶柯提取物40%~60%、罗汉果苷5%~15%、柠檬提取物10%~30%,余量为辅料,所述各原料重量百分比的总和不超过100%。
3.根据权利要求2所述的一种木姜叶柯饮料,其特征在于:各原料按质量百分比的含量为:木姜叶柯提取物40%、罗汉果苷15%、柠檬提取物18%,余量为辅料,所述各原料重量百分比的总和不超过100%。
4.根据权利要求3所述的一种木姜叶柯饮料,其特征在于:所述辅料为β-环糊精和碳酸氢纳。
5.根据权利要求1-4任一项所述的一种木姜叶柯饮料制备方法,其特征在于:包括以下步骤:
S1:将木姜叶柯老叶和嫩叶以及枝条冷冻干燥后粉碎,得到木姜叶柯粉末;
S2:将步骤S1得到的木姜叶柯粉末和70%的乙醇溶液加入压力容器罐,加入符合卫生标准的清水,将压力容器罐压力控制在10~20MPa,加入热水温度在80~100℃保持10min~50min,停止加热水,待压力容器罐内压力恢复到常压时,采用目数为2~8的金属过滤网过滤,收到滤液;
S3:当上清液流出完后再重复步骤S2对滤渣进一步压榨,继续收集滤液;
S4:将步骤S2和步骤S3中获得的滤液进行合并,再对合并后的滤液在浓缩仓进行减压浓缩,减压浓缩时浓缩仓内压强为80~90KPa,温度控制在60~80℃,减压浓缩时间为20min~25min,滤液浓缩成膏状;
S5:将浓缩膏喷雾干燥,粉碎过筛,备用;
S6:对柠檬原果进行清洗处理后除去外果皮,获得去外果皮柠檬果,将柠檬果切片机上切片3~4毫米,重量考虑一片9~12克,然后将柠檬片上的柠檬核去掉获得柠檬果片,将去除好的柠檬片放入微波灭菌机中灭菌,将柠檬果片先在-30℃冷冻4小时,然后在60℃真空干燥25小时,获得干柠檬果片,将柠檬果片进行粉碎获得柠檬果粉;
S7:在木姜叶柯浓缩膏粉中加入罗汉果苷、柠檬果粉和辅料,混合均匀,放入灭菌室进行115~125℃高温灭菌,冷却至94~96℃后取出,继续冷却至80~85℃后灌装,得到木姜叶柯饮料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110015884.8A CN112841472A (zh) | 2021-01-07 | 2021-01-07 | 一种木姜叶柯饮料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110015884.8A CN112841472A (zh) | 2021-01-07 | 2021-01-07 | 一种木姜叶柯饮料及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112841472A true CN112841472A (zh) | 2021-05-28 |
Family
ID=76004518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110015884.8A Pending CN112841472A (zh) | 2021-01-07 | 2021-01-07 | 一种木姜叶柯饮料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112841472A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114009556A (zh) * | 2021-10-18 | 2022-02-08 | 成都农业科技中心 | 一种高抗氧化活性木姜叶柯水果康普茶及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1849921A (zh) * | 2006-05-23 | 2006-10-25 | 四川省安岳县华通柠檬开发有限公司 | 微波真空冷冻干燥柠檬片的制造方法 |
CN108740625A (zh) * | 2018-06-14 | 2018-11-06 | 中社旭日食品集团有限公司 | 一种木姜叶柯植物饮料及其制备方法 |
CN109497536A (zh) * | 2019-01-18 | 2019-03-22 | 青岛科技大学 | 一种木姜叶柯罗汉果功能性食品及其制备方法 |
CN110946196A (zh) * | 2019-11-22 | 2020-04-03 | 中南大学 | 木姜叶柯冲剂及制备方法 |
-
2021
- 2021-01-07 CN CN202110015884.8A patent/CN112841472A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1849921A (zh) * | 2006-05-23 | 2006-10-25 | 四川省安岳县华通柠檬开发有限公司 | 微波真空冷冻干燥柠檬片的制造方法 |
CN108740625A (zh) * | 2018-06-14 | 2018-11-06 | 中社旭日食品集团有限公司 | 一种木姜叶柯植物饮料及其制备方法 |
CN109497536A (zh) * | 2019-01-18 | 2019-03-22 | 青岛科技大学 | 一种木姜叶柯罗汉果功能性食品及其制备方法 |
CN110946196A (zh) * | 2019-11-22 | 2020-04-03 | 中南大学 | 木姜叶柯冲剂及制备方法 |
Non-Patent Citations (3)
Title |
---|
《国外科技动态》编辑部: "《国外消费品资料选编 2》", 30 June 1984, 科学技术文献出版社 * |
吴东蓉等: "木姜叶柯研究进展", 《贵州农机化》 * |
李培实等: "《小学自然教师手册》", 30 June 1988, 人民教育出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114009556A (zh) * | 2021-10-18 | 2022-02-08 | 成都农业科技中心 | 一种高抗氧化活性木姜叶柯水果康普茶及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101370841B1 (ko) | 구아바 잎 엑기스 분말 및 그의 제조방법 | |
CN104054769B (zh) | 一种治疗心血管疾病的功能面包及其制作方法 | |
CN106901118B (zh) | 具有辅助降血糖作用的固体饮料及其制备方法 | |
JPWO2007007732A1 (ja) | アディポネクチン濃度上昇剤 | |
CN101612315A (zh) | 一种用于调整人体机能的中药复方制剂 | |
CN101961341A (zh) | 罗汉果甜甙降糖功能的应用 | |
CN104770727A (zh) | 一种复合黄秋葵降糖冻干粉及制备方法 | |
CN103830496A (zh) | 一种辅助降糖的组合物 | |
CN108174951A (zh) | 一种辅助降血糖的桑叶黄精茶制备方法 | |
CN102835533A (zh) | 一种复方沙棘黑银杏果仁夹心巧克力的制备方法 | |
CN103549261B (zh) | 辅助降血脂的保健汤圆及其制作方法 | |
CN112841472A (zh) | 一种木姜叶柯饮料及其制备方法 | |
CN103263054B (zh) | 一种降血压功能性饮品 | |
CN108936237A (zh) | 一种含中药组分的健脾益胃粗粮粑粑及其制备方法 | |
CN101006849B (zh) | 一种榴莲提取物及其制备方法及应用 | |
CN105831318A (zh) | 一种多肽降糖茶及其制作方法 | |
CN109820123A (zh) | 一种改善微循环的植物饮品及其制备方法 | |
CN104225573A (zh) | 一种降血糖、降血脂组合物及其制备方法 | |
JP6273440B2 (ja) | Glp−1産生促進剤、dppiv阻害剤及びグルコース吸収阻害剤 | |
KR101445573B1 (ko) | 꾸지뽕을 이용한 건강 보조 식품용 효소액 및 환과 그 제조방법 | |
CN105582408A (zh) | 一种辣木降脂茶及其制备方法 | |
CN112022939A (zh) | 一种用于高血压合并高脂血症的胶囊及其制备方法 | |
CN110693931A (zh) | 一种养生牛蒡咀嚼片配方及其制备方法 | |
CN110226721A (zh) | 一种具有辅助降血糖功能的组合物 | |
CN108208076A (zh) | 一种巧克力舒芙蕾及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210528 |
|
WD01 | Invention patent application deemed withdrawn after publication |